
IgGenix emerges from stealth with $10 million Series A hoping to re-engineer allergic cascade
A little over six months after the FDA approved the first treatment for peanut allergies, a new biotech has emerged hoping to break through in a field that’s seen virtually no innovation.
IgGenix came out of stealth mode Tuesday morning, announcing a $10 million Series A round to get the company started. The California-based biotech aims to focus not just on peanuts, but all types of food allergies and related serious conditions by developing a platform that can interfere with the allergic cascade. Financing was led by Khosla Ventures and joined by Parker Ventures.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.